Genetics, epigenetics, infection as an environmental factor, functional findings for the immune system, and a therapeutic approach with anti-inflammatory therapy provide evidence for a pivotal role of the immune system in schizophrenia. This field, therefore, should focus more on further schizophrenia research.
AkhondzadehSTabatabaeeMAminiHAhmadi AbhariSAAbbasiSHBehnamB (2007) Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res90: 179–185.
2.
BrownAS (2006) Prenatal infection as a risk factor for schizophrenia. Schizophr Bull32: 200–202.
3.
ChavesCMarqueCRChaudhryIB (2009) Short-term improvement by minocycline added to olanzapine antipsychotic treatment in paranoid schizophrenia. Schizophrenia BullSuppl. 1: 354–354.
4.
CostaEDongEGraysonDRGuidottiARuzickaWVeldicM (2007) Reviewing the role of DNA (cytosine-5) methyltransferase overexpression in the cortical GABAergic dysfunction associated with psychosis vulnerability. Epigenetics2: 29–36.
5.
KawasakiHIwamuroS (2008) Potential roles of histones in host defense as antimicrobial agents. Infect Disord Drug Targets8: 195–205.
6.
KnightJGMenkesDBHightonJAdamsDD (2007) Rationale for a trial of immunosuppressive therapy in acute schizophrenia. Mol Psychiatry12: 424–431.
7.
MednickSAMachonRAHuttunenMOBonettD (1988) Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry45: 189–192.
8.
MüllerNRiedelMScheppachC (2002) Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry159: 1029–1034.
9.
MüllerNSchwarzMJ (2006) Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders. Expert Rev Neurother6: 1017–1038.
10.
MüllerNSchwarzMJ (2007) The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J Neural TransmSuppl. 72: 269–280.
11.
PurcellSMWrayNRStoneJL (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature460: 748–752.
12.
RapaportMHDelrahimKKBreseeCJMadduxREAhmadpourODolnakD (2005) Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry57: 1594–1596.
13.
RogersDPGoldsmithCA (2009) Treatment of schizophrenia in the 21st century: beyond the neurotransmitter hypothesis. Expert Rev Neurother9: 47–54.
14.
ShiJLevinsonDFDuanJ (2009) Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature460: 753–757.
15.
StefanssonHOphoffRASteinbergS (2009) Common variants conferring risk of schizophrenia. Nature460: 744–747.
16.
van BerckelBNBossongMGBoellaardR (2008) Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry64: 820–822.
17.
WinterCDjodari-IraniASohrR (2009) Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. Int J Neuropsychopharmacol12: 513–524.
18.
WrightPNimgaonkarVLDonaldsonPTMurrayRM (2001) Schizophrenia and HLA: a review. Schizophr Res47: 1–12.
19.
ZuckermanLWeiner I (2005) Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiatr Res39: 311–323.
